Michael L. Rosenzweig

City Of Hope National Medical Center — United States

Environmental Science · Physical Sciences

61h-index22.7kcitations232works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ecology and Vegetation Dynamics Studies(61), Animal Ecology and Behavior Studies(58), Plant and animal studies(40), Wildlife Ecology and Conservation(30), Mathematical and Theoretical Epidemiology and Ecology Models(23)

Publications232 total

Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)
Blood·2025
Safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel) in Relapsed/Refractory multiple myeloma (RRMM)
Blood·2025Open Access
Real World Accelerated Step-Up Dosing of Teclistamab and Talquetamab in the Outpatient Setting is Feasible and Associated with Low Incidence of Cytokine Release Syndrome
Clinical Lymphoma Myeloma & Leukemia·2025
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
Blood Cancer Journal·2025· 1 citedOpen Access
Clonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation
JNCI Journal of the National Cancer Institute·2025· 1 citedOpen Access
Abstract A018: Association of clonal hematopoiesis and diabetes with mortality after autologous hematopoietic cell transplantation
Cancer Research·2025
Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
Blood·2024· 2 citedOpen Access
P-392 A Phase 1 Trial of 225Actinium-DOTADaratumumab in Patients with Daratumumab-Refractory Multiple Myeloma: Results from First Cohorts
Clinical Lymphoma Myeloma & Leukemia·2024
P-031 Phase I Study to Evaluate Cellular Immunotherapy Using CS-1 Targeting Autologous CAR T Cells in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2024
Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration
Frontiers in Immunology·2024Open Access
Trial in Progress: A Phase 1/1a Study of Venetoclax, Ixazomib and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis PA160 (#328)
2024
The value of AI for enhancing suspicion of cardiac amyloidosis using electrocardiography and echocardiography: A narrative review PA12 (#516)
2024
Diagnostic utility of left atrial and right ventricular strain analyses in patients with AL amyloidosis PB107 (#244)
2024
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Vaccines·2023· 4 citedOpen Access
Supplementary Materials and Methods and Supplementary Figure Legends 1-7 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
2023Open Access
Supplementary Tables 1-4 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
2023Open Access
Data from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
2023Open Access
Supplementary Tables 1-4 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
2023Open Access
Supplementary Materials and Methods and Supplementary Figure Legends 1-7 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
2023Open Access
Supplementary Figures 1- 7 from ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Zvika Abramsky(8), Stuart L. Pimm(2), William A. Mitchell(2), Berry Pinshow(2), G. P. Patil(2), William M. Schaffer(2), Robert H. MacArthur(1), Mark A. Davis(1), Matthew K. Chew(1), Richard J. Hobbs(1), Ariel E. Lugo(1), John J. Ewel(1), Geerat J. Vermeij(1), James H. Brown(1), Mark R. Gardener(1), Scott P. Carroll(1), Ken Thompson(1), Steward T. A. Pickett(1), Juliet C. Stromberg(1), Peter Del Tredici(1)